We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
E-therapeutics Plc | LSE:ETX | London | Ordinary Share | GB00B2823H99 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 9.00 | 9.00 | 9.50 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 475k | -8.27M | -0.0142 | -6.34 | 52.55M |
Four Clinical Trials and Striking Results from Discovery Engine
e-Therapeutics plc (AIM:ETX), the drug discovery and development company, today announces its full year results for the year ended 31 January 2015.
Operational highlights
Financial highlights
Professor Malcolm Young, CEO of e-Therapeutics, said:
“The past 12 months have seen a strong acceleration of progress, both clinically and in discovery.
“In the clinic, we have had four clinical trials ongoing in Europe and the US. We have had positive dosing and safety results for our lead product, ETS2101 and we are moving into the next phase of testing in two cancer indications. We have also seen good progress with ETS6103 and anticipate the completion of its phase IIb later this year.
“Most exciting has been the striking productivity of our drug discovery engine. The investment and enhancements we have made over the past two years are paying dividends, not only with the number of molecules we can now screen, but in the groundbreaking yields we are observing. We have a wealth of active molecules to choose from to take forward into development.
“The combination of these successes in 2014/15 with a strong balance sheet heralds another twelve months of major advancement and progress.”
For the full release, please visit the company website at www.etherapeutics.co.uk.
About e-Therapeutics
e-Therapeutics is an AIM-quoted biotechnology company with a proprietary platform in network pharmacology, an innovative new approach to drug discovery based on advances in network science and chemical biology. The Company’s discovery and development activity is focused in cancer and disorders of the nervous system. e-Therapeutics is based at sites in Oxford and Newcastle, UK. For more information about the Company please visit www.etherapeutics.co.uk.
e-Therapeutics plcMalcolm Young, CEO / Steve Medlicott, Finance DirectorTel: +44 (0)1993 883 125www.etherapeutics.co.ukorN+1 SingerAubrey Powell / Jen BoorerTel: +44 (0) 20 7496 3000www.n1singer.comorInstinctif PartnersMelanie Toyne Sewell / Emma BarlowTel: +44 (0) 20 7457 2020e-therapeutics@instinctif.com
1 Year E-therapeutics Chart |
1 Month E-therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions